15th Oct 2020 07:33
Ap19
FORM 8.3 Amendment to Sales
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
| Name of person dealing (Note 1) | Barclays PLC. | |
| Company dealt in | WILLIS TOWERS WATSON PLC | |
| Class of relevant security to which the | ORD | |
| dealings being disclosed relate (Note 2) | ||
| Date of dealing | 12 October 2020 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Class of relevant security: | ORD | ||||
| Long | Short | ||||
| Number | (%) | Number | (%) | ||
(1) | Relevant securities |
|
|
|
|
2,563,276 | 1.99% | 467,804 | 0.36% | ||
|
|
|
| ||
(2) | Derivatives (other than options): |
|
|
|
|
362,656 | 0.28% | 388,524 | 0.30% | ||
|
|
|
| ||
(3) | Options and agreements to |
|
|
|
|
| purchase/sell: | 0 | 0.00% | 0 | 0.00% | |
|
|
|
| ||
| TOTAL: |
|
|
|
| |
2,925,932 | 2.27% | 856,328 | 0.66% | ||
|
|
|
| ||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: | Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities |
|
| ||||
(2) Derivatives (other than options) |
|
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total |
|
| ||||
| ||||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
| Purchase/sale | Number of relevant securities | Price per unit |
Purchase | 1 | 217.5050 USD |
Purchase | 1 | 216.9000 USD |
Purchase | 2 | 216.7181 USD |
Purchase | 2 | 214.9300 USD |
Purchase | 3 | 217.3200 USD |
Purchase | 6 | 216.9390 USD |
Purchase | 7 | 216.1600 USD |
Purchase | 32 | 214.4700 USD |
Purchase | 40 | 216.1680 USD |
Purchase | 63 | 216.7741 USD |
Purchase | 100 | 217.5900 USD |
Purchase | 132 | 216.2533 USD |
Purchase | 164 | 215.9912 USD |
Purchase | 200 | 216.9700 USD |
Purchase | 350 | 214.8658 USD |
Purchase | 375 | 216.5321 USD |
Purchase | 457 | 216.0115 USD |
Purchase | 1,374 | 216.1215 USD |
Purchase | 1,573 | 217.0301 USD |
Purchase | 1,850 | 216.1554 USD |
Purchase | 1,880 | 217.0304 USD |
Purchase | 1,897 | 215.7356 USD |
Purchase | 2,416 | 215.7375 USD |
Purchase | 3,058 | 217.0223 USD |
Purchase | 3,108 | 216.9647 USD |
Purchase | 3,468 | 215.7663 USD |
Purchase | 3,782 | 216.3231 USD |
Purchase | 4,000 | 215.8638 USD |
Purchase | 4,204 | 216.1086 USD |
Purchase | 12,001 | 216.7179 USD |
Purchase | 14,640 | 216.7006 USD |
Purchase | 13,371 | 217.0300 USD |
Purchase | 117,236 | 214.2956 USD |
Sale | 1 | 216.0600 USD |
Sale | 2 | 215.6550 USD |
Sale | 10 | 215.7369 USD |
Sale | 25 | 216.9500 USD |
Sale | 92 | 212.9100 USD |
Sale | 97 | 213.3900 USD |
Sale | 100 | 215.8050 USD |
Sale | 160 | 217.0050 USD |
Sale | 185 | 216.7650 USD |
Sale | 200 | 215.8350 USD |
Sale | 256 | 216.5212 USD |
Sale | 300 | 217.1754 USD |
Sale | 330 | 216.6290 USD |
Sale | 347 | 216.9480 USD |
Sale | 413 | 216.8508 USD |
Sale | 589 | 216.8633 USD |
Sale | 608 | 216.5452 USD |
Sale | 640 | 216.9180 USD |
Sale | 650 | 214.1715 USD |
Sale | 800 | 215.9580 USD |
Sale | 903 | 213.0932 USD |
Sale | 1,056 | 216.6504 USD |
Sale | 1,343 | 216.7184 USD |
Sale | 1,345 | 216.2111 USD |
Sale | 1,578 | 217.0309 USD |
Sale | 2,618 | 215.4430 USD |
Sale | 2,689 | 216.2891 USD |
Sale | 2,990 | 215.9810 USD |
Sale | 3,057 | 217.0223 USD |
Sale | 3,433 | 216.9462 USD |
Sale | 3,934 | 216.3505 USD |
Sale | 7,063 | 216.9857 USD |
Sale | 12,408 | 214.4127 USD |
Sale | 12,601 | 217.0300 USD |
Sale | 12,963 | 215.7770 USD |
Sale | 14,327 | 216.7458 USD |
Sale | 20,000 | 213.4119 USD |
Sale | 22,292 | 214.9205 USD |
Sale | 58,618 | 214.2956 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (Note 5) |
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
| Is a Supplemental Form 8 (Open Positions) attached? | NO |
| Date of disclosure: | 15 Oct 2020 |
| Contact name: | Large Holdings Regulatory Operations |
| Telephone number: | 020 3134 7213 |
| If a connected EFM, name of offeree/offeror with which connected | |
| If a connected EFM, state nature of connection |
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014006073/en/
Copyright Business Wire 2020
Related Shares:
Barclays